Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

The Trust Test

Biomarin

BioMarin eyes haemophilia therapy filing, but data scares investors

Doubts remain on longer term efficacy

- PMLiVE

Oxford Biomedica gets £53m cash injection from Novo venture arm

Cell and gene therapy specialist needs to invest to stay ahead

- PMLiVE

Ogilvy Health UK launches workplace learning company

Tailors learning to pharma industry roles

- PMLiVE

Nucleus Global launches Nucleus POLAR™, a state-of-the-art expert search engine and engagement management tool

Nucleus POLAR™ uses cutting-edge technology to enable rapid external expert identification, mapping and centralised engagement planning.

Nucleus Global

- PMLiVE

Lucid Group and Vivid Medical Communications make the cut at this year’s Communiqué awards

Lucid Group has been shortlisted for the Porterhouse Medical Group Award for Medical Consultancy of the Year award, illustrating once again the magic that Lucid brings to the industry.Vivid, a...

Lucid Group Communications Limited

- PMLiVE

Am I wrong to be apprehensive about gene therapy?

Is the introduction of gene therapy going to be smooth sailing? Origin's Strategic Solutions Director, Su Smith, shares her thoughts.

Bedrock Healthcare Communications

- PMLiVE

Healthcare communications in the mobile age

By Matt Royle

Patient Centricity On Trial

Today, 40 million patients are needed for over 300,00 clinical trials, worldwide. This year’s white paper explores how bringing the patient experience front and centre in clinical trials could revolutionise...

Havas Lynx

19 Patient Centricity on Trial

Clinical trials are broken and only patients can help us fix them. If we let them.

Havas Lynx

- PMLiVE

Novartis secures US approval – and payers’ blessing – for $2m gene therapy Zolgensma

Novel financing deal could be sector's future

- PMLiVE

European elections: Eurosceptics and Greens rise, but big parties hold on

Horse-trading over top jobs now begins

Novartis day

FDA clears Novartis’ new breast cancer drug Piqray

Blockbuster potential for PI3K drug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links